Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system.

Abstract

Dysfibrogenemias are characterized by the production of abnormally functioning fibrinogen, occurring in the presence of liver disease, medication toxicity, malignancy, or genetic mutation. Here, we report a patient with multiple, separate episodes of hepatic portal system thromboses associated with dysfibrinogenemia. Molecular studies identified the presence of a 554Arg→Cys mutation in the fibrinogen Aα gene, previously identified as Fibrinogen Dusart (also known as Fibrinogen Paris V and Fibrinogen Chapel Hill). This case further illustrates the association of this dysfibrinogenemia with a unique thrombophilic manifestation.

• Authors: Yu-Min Shen, Vinh Trang, Ravi Sarode, Stephen Brennan
• Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 25 Issue 4 Pg. 392-4 (Jun 2014) ISSN: 1473-5733 [Electronic] England
• PMID: 24384913 (Publication Type: Case Reports, Journal Article)

Chemical References

• fibrinogen Aalpha
• Fibrinogen

Topics

• Adult
• Afibrinogenemia (blood, diagnosis, genetics)
• Diagnosis, Differential
• Fibrinogen (genetics)
• Hepatitis C (blood, genetics)
• Humans
• Male
• Portal System (physiopathology)
• Thrombosis (blood, diagnosis, genetics)